RVAC Medicines
Signal active
Organization
Contact Information
Overview
RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas. The company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. It's cutting-edge GMP manufacturing facilities that will advance its platform technologies through in-house research and development and external partnerships, enabling the production of cutting-edge mRNA and nucleic acid delivery technologies.
RVAC Medicines was founded in 2021 and is based in Singapore.
About
Industries
Biotechnology, Medical, Product Research
Founded
2021
Employees
51-100
Headquarters locations
Asia
Social
N/A
Profile Resume
RVAC Medicines headquartered in Asia, operates in the Biotechnology, Medical, Product Research sector. The company focuses on Biotechnology and has secured $1.7B in funding across 12 round(s). With a team of 51-100 employees, RVAC Medicines is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - RVAC Medicines, raised $140.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
1
Investors
4
Lead Investors
0
Total Funding Amount
$140.0M
Details
1
RVAC Medicines has raised a total of $140.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 140.0M |
Investors
RVAC Medicines is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Suhhong Hur | - | FUNDING ROUND - Suhhong Hur | 140.0M |
| GS Holdings | - | FUNDING ROUND - GS Holdings | 140.0M |
| RVAC Medicines | - | FUNDING ROUND - RVAC Medicines | 140.0M |
| Pavilion Capital | - | FUNDING ROUND - Pavilion Capital | 140.0M |
Recent Activity
There is no recent news or activity for this profile.